A recent Wall Street Journal article addressed the intersection of two major macro trends within the biotech industry: the rise of China-based innovation-driven biotech companies and the continued sourcing of new discoveries globally by large pharma. Over the past few years, the Chinese biotech and pharmaceutical industries have begun a pivot from generic drugs to truly novel biology. This is reflected in growing investments in novel technology platforms, people and patents, leading to new drugs and important publications. Global pharma companies have taken notice through innovation centers and in-licensing Chinese-discovered biotech drug candidates. At the same time, Chinese companies are increasingly scouting US and EU markets to develop in Greater China and Globally. The article clearly identifies that China is early on a path to becoming a leader in innovative science. Companies like 3SBio, Innovent and Zai Labs are emerging as exciting companies. The Chinese biotech investment environment will continue to pull talent from the US and EU back to China to become the next generation industry leaders. As in all things, the scale of China provides interesting opportunities.
Click here for the full article:
https://www.wsj.com/articles/china-emerges-as-powerhouse-for-biotech-drugs-1491816607